Rossari Biotech Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹698 Cr +19.1% YoYSee revenue, profit and what management said. You are viewing Q4 FY26.
RB

Rossari Biotech

Q4 FY26Chemicals & Petrochemicals

Rossari Biotech Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹685Cr
+18.1% YoY
+17.7% QoQ
Net profit
₹46Cr
+35.3% YoY
+39.4% QoQ
Margin
11%
−1 pp YoY
−1 pp QoQ

Rossari Biotech Q4 FY26 key numbers

Revenue
CAPEX of Rs. 50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments.

As stated in Rossari Biotech's Q4 FY26 earnings call transcript · published 24 Aug 2026. Reported figures, not investment advice.

Price₹499
Market cap₹2.8K Cr
P/E18.4

The short version

Targeting a minimum 15% growth in FY27 driven by expansions in agro, pharma, personal care, and textile exports (including markets like Bangladesh, Thailand, Turkey, and Brazil). The company expects a minimum of 15% revenue growth in FY27 driven by expansion in personal care, agro, textile exports, and animal health and nutrition (AHN) segments.

From Rossari Biotech's Q4 FY26 earnings-call transcript · updated 24 Aug 2026.

Revenue & Sales Performance

  • Targeting a minimum 15% growth in FY27 driven by expansions in agro, pharma, personal care, and textile exports (including markets like Bangladesh, Thailand, Turkey, and Brazil).
  • New premix facility in Animal Health Nutrition (AHN) expected to ramp up revenues starting FY27, supporting growth.
  • CAPEX of Rs. 50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments.
  • Growth expected over the next 2-3 years through new customer additions and expansion in high-margin segments such as pharma, oil and gas, aroma, personal care, food processing, and institutional chemicals.
  • Core B2B businesses to drive growth with latent growth in Agro, Textile, AHN, and Personal Care.

2 more points from Rossari Biotech's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Rossari Biotech said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • FY27 CAPEX plan is Rs. 50 crore to Rs. 75 crore, including:
  • New pharma facility expansion
  • Aroma chemical facility expansion
  • Earlier large CAPEX plans (Rs. 190 crore across multiple sites) have been rephased due to market conditions; some parts postponed to optimize cash flow and returns
  • New R&D facility set up in Navi Mumbai consolidating existing operations, supporting faster innovation and scale-up
  • Ethoxylation capacity expanded to 66,000 metric tons per annum at Dahej, improving supply reliability
  • Ongoing focus on capacity utilization and operational efficiencies to support growth

2 more points from Rossari Biotech's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Rossari Biotech said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Relevant points related to demand and order pipeline include: - Utilization levels for ethoxylation capacity are very high (90%-100%), running continuously, indicating strong order demand. - The company sees a good pipeline of projects across its sales and business development teams worked on in the last 12 months. - Orders remain robust. - Growth drivers include North America for personal care and agro businesses, ramping up exports in textiles through Bangladesh, Southeast Asia, Thailand, Turkey, and Brazil.

2 more points from Rossari Biotech's call on order book

Create a free account to keep reading this call

Rossari Biotech — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Rossari Biotech Q4 FY26 results — key figures

Rossari Biotech Q4 FY26 reported results vs Q4 FY25, ₹ crore
₹ CrQ4 FY26Q4 FY25YoYQ3 FY26QoQ
Revenue685580+18.1%582+17.7%
Operating profit (EBITDA)7769+11.6%69+11.6%
Operating margin11%12%-1 pp12%-1 pp
Profit before tax6448+33.3%43+48.8%
Net profit (PAT)4634+35.3%33+39.4%
EPS (₹)8.306.22+33.4%5.92+40.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹698 Cr, net profit ₹39 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Indian Phosphate (Q4 FY26)

    H2 FY26 Revenue (Consolidated):** ₹580.25 Cr, up from ₹451.59 Cr in H2 FY25 — a year-on-year increase of ₹128.66 Cr. Key investor presentation takeaways from In

  • Paragon Fine (Q4 FY26)

    Revenue for H2FY26:** Rs 68.88 Cr, up 7.41% YoY from Rs 64.13 Cr in H2FY25 (Page 22). Key investor presentation takeaways from Paragon Fine's Q4 FY26 investor p

  • IVP (Q4 FY26)

    Q4 FY26 revenue from operations: ₹164.44 crore . Key investor presentation takeaways from IVP's Q4 FY26 investor presentation — and how it ranks against sector

  • Vishnu Chemicals (Q4 FY26)

    Q4 FY26 Operating Revenues: ₹450.3 crore, up 14.7% YoY from ₹392.6 crore in Q4 FY25 (Page 5). Key investor presentation takeaways from Vishnu Chemicals Ltd's Q4

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Rossari Biotech and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Rossari Biotech Q4 FY26 results?

Targeting a minimum 15% growth in FY27 driven by expansions in agro, pharma, personal care, and textile exports (including markets like Bangladesh, Thailand, Turkey, and Brazil). The company expects a minimum of 15% revenue growth in FY27 driven by expansion in personal care, agro, textile exports, and animal health and nutrition (AHN) segments.

What is Rossari Biotech share price analysis?

Rossari Biotech currently shows a neutral. The stock trades at a P/E of 18.4 with a market cap of ₹2,779 Cr. Investors should review the full earnings analysis for detailed insights.

Is Rossari Biotech planning capital expenditure?

FY27 CAPEX plan is Rs. 50 crore to Rs. 75 crore, including:.

Keep Rossari Biotech on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.